Drug Trial Radar · NCT06843044
Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders
Last checked: Nov 20, 2026Latest source record: Jul 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Jan 13, 2025
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Valenta Pharm JSCIndustry
- Sponsor type
- Industry
- First posted
- Feb 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study is to evaluate the efficacy and safety of the drug Ranquilon, 1 mg tablets, at a dosage of 6 mg/day compared to the drug Afobazole, 10 mg tablets, at a dosage of 30 mg/day for the treatment of patients with anxiety disorders due to neurasthenia and adjustment disorders.
Conditions
- Anxiety
- Neurasthenia
- Adjustment Disorders
Interventions
RanquilonDrug
1 mg tablets
AfobazoleDrug
10 mg tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of patients with a significant reduction in anxiety levels (by 50% or more) on Hamilton Anxiety Rating Scale (HARS) compared to baseline on Day 29 ± 1 (Visit 3)Time frame: Day 29 ± 1 (Visit 3)
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Engels Psychiatric Hospital State Health Care Institution of the Ministry of Health of the Saratov Region
Engel's, Russia · Recruiting
Unimed-C Jsc
Moscow, Russia · Recruiting
Aurora MedFort LLC
Saint Petersburg, Russia · Recruiting
Limited Liability Company "Research Center Eco-Safety"
Saint Petersburg, Russia · Recruiting
Limited Liability Company "Stepmed Clinic"
Saint Petersburg, Russia · Recruiting
Saratov City Psychoneurological Dispensary
Saratov, Russia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.